Must be followed and passed . In this sense, a drug must be subjected to investigations from the first experiments in animals to the different phases of a clinical trial in humans. Thus, in spain, for a new drug to be approved by the spanish agency for medicines and health products and to be marketed, once the preclinical phase (animal testing) has been completed, it must pass the following three phases of clinical trials in humans . In them, the safety and efficacy of the new developed molecule is evaluated. Clinical trials usually last an average of 10 years and only about 20% of drugs tested in humans end up exceeding all requirements and are marketed.

With regard to alzheimer's disease, no clinical trial has yet succeeded in developing a drug that cures this disease. Currently, pharmacological treatments for alzheimer's disease have little effect on its evolution. Advances to date have failed to halt or reverse the disease. In fact, more than 200 molecules developed , candidates to be the treatment, have failed over the last decade. Therefore, it is necessary to continue researching in the search for new drugs that improve the prognosis and quality e commerce photo editing of life of patients with alzheimer's. Based on clinical trials already conducted, the key to modifying the course of the disease could lie in a multiple treatment approach. That is, use several drugs that act on different targets, combine them with

a "brain-healthy" lifestyle and promote, for example, cognitive stimulation . Is there hope for a cure for alzheimer's disease? Despite the numerous investigations carried out in alzheimer's disease, developing the molecule that cures this disease remains a challenge. In fact, if we take a look at the largest medical literature database in existence ( medline ), we can find more than 129,000 studies related to this disease. The objectives to be pursued with the latest research are: develop medications not only capable of acting on the symptoms of the disease but also on the appearance and